Short Interest in Moleculin Biotech, Inc. (NASDAQ:MBRX) Increases By 108.8%

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the target of a significant increase in short interest in the month of January. As of January 15th, there was short interest totaling 358,088 shares, an increase of 108.8% from the December 31st total of 171,538 shares. Approximately 17.9% of the shares of the company are short sold. Based on an average daily trading volume, of 156,481 shares, the short-interest ratio is currently 2.3 days. Based on an average daily trading volume, of 156,481 shares, the short-interest ratio is currently 2.3 days. Approximately 17.9% of the shares of the company are short sold.

Moleculin Biotech Trading Up 0.2%

MBRX stock traded up $0.01 during mid-day trading on Friday, reaching $4.29. 36,983 shares of the stock traded hands, compared to its average volume of 136,496. Moleculin Biotech has a 52-week low of $3.13 and a 52-week high of $91.25. The stock’s fifty day moving average is $4.94 and its 200-day moving average is $10.16. The company has a market cap of $8.75 million, a P/E ratio of -0.13 and a beta of 1.62.

Moleculin Biotech (NASDAQ:MBRX) last released its earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.07. Equities research analysts expect that Moleculin Biotech will post -7.98 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on MBRX. Wall Street Zen lowered Moleculin Biotech to a “strong sell” rating in a report on Friday, October 3rd. Roth Mkm reaffirmed a “buy” rating on shares of Moleculin Biotech in a report on Monday, December 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a report on Thursday, January 22nd. Finally, HC Wainwright restated a “buy” rating and set a $22.00 price objective (up previously from $4.00) on shares of Moleculin Biotech in a research report on Thursday, December 11th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $61.00.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.